[go: up one dir, main page]

CA2238762A1 - Derives 2-thioxo-imidazolin-4-one et leur utilisation pour augmenter la cholesterolemie a lipoproteine de haute densite - Google Patents

Derives 2-thioxo-imidazolin-4-one et leur utilisation pour augmenter la cholesterolemie a lipoproteine de haute densite Download PDF

Info

Publication number
CA2238762A1
CA2238762A1 CA002238762A CA2238762A CA2238762A1 CA 2238762 A1 CA2238762 A1 CA 2238762A1 CA 002238762 A CA002238762 A CA 002238762A CA 2238762 A CA2238762 A CA 2238762A CA 2238762 A1 CA2238762 A1 CA 2238762A1
Authority
CA
Canada
Prior art keywords
thioxo
carbon atoms
imidazolidin
ethyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002238762A
Other languages
English (en)
Inventor
Sie-Yearl Chai
Theodore Sylvester Sulkowski
Donald Peter Strike
Hassan Mahmoud Elokdah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/563,325 external-priority patent/US5554607A/en
Application filed by Individual filed Critical Individual
Publication of CA2238762A1 publication Critical patent/CA2238762A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composés et procédé permettant d'augmenter la concentration en cholestérol à lipoprotéines de haute densité (HDL) dans le sang d'un mammifère nécessitant une concentration accrue de cholestérol HDL, ledit procédé consistant à administrer audit mammifère, par voie orale ou parentérale, un composé de formule (I). Dans la formule (I), R représente alkyle; un hétérocycle N, O, ou S aromatique substitué ou non; aryle, arylalkyle, benzhydryle ou indanyl substitué ou non dans lequel les substituants peuvent être un, deux ou trois éléments indépendamment sélectionnés dans le groupe formé par: alkyle, alcoxy, akylthio, alcényle, alcynyle, halo, perfluoroalkyle, perfluoroalcoxy ou hydroxy; et R?1¿ représente aryle, alkyle, alcényle, alcynyle ou aryle substitué dans lequel les substituants peuvent être un, deux ou trois éléments indépendamment sélectionnés dand le groupe formé par: alkyle, alcoxy, alkythio, alcényle, alcynyle, halo, perfluoroalkyle, perfluoroalcoxy ou hydroxy.
CA002238762A 1995-11-28 1996-11-25 Derives 2-thioxo-imidazolin-4-one et leur utilisation pour augmenter la cholesterolemie a lipoproteine de haute densite Abandoned CA2238762A1 (fr)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US765495P 1995-11-28 1995-11-28
US766695P 1995-11-28 1995-11-28
US765895P 1995-11-28 1995-11-28
US766195P 1995-11-28 1995-11-28
US766595P 1995-11-28 1995-11-28
US60/007,666 1995-11-28
US60/007,658 1995-11-28
US08/563,325 US5554607A (en) 1995-11-28 1995-11-28 Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of atherosclerosis
US08/563,325 1995-11-28
US60/007,661 1995-11-28
US60/007,654 1995-11-28
US60/007,665 1995-11-28

Publications (1)

Publication Number Publication Date
CA2238762A1 true CA2238762A1 (fr) 1997-06-05

Family

ID=27555583

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002238762A Abandoned CA2238762A1 (fr) 1995-11-28 1996-11-25 Derives 2-thioxo-imidazolin-4-one et leur utilisation pour augmenter la cholesterolemie a lipoproteine de haute densite

Country Status (5)

Country Link
EP (1) EP0876355A1 (fr)
JP (1) JP2000501100A (fr)
AU (1) AU1127697A (fr)
CA (1) CA2238762A1 (fr)
WO (1) WO1997019932A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455566B1 (en) 1997-09-03 2002-09-24 Wyeth Substituted 1-aryl-3-heteroaryl-thioureas (or isothioureas) as antiatherosclerotic agents
TW415942B (en) * 1997-09-03 2000-12-21 American Home Prod Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents
CA2339090C (fr) * 1998-08-31 2009-11-17 Sentron Medical, Inc. Derives de methimazole et thiones cycliques tautomeres permettant de traiter les maladies auto-immunes
WO2003024441A1 (fr) 2001-09-14 2003-03-27 Shionogi & Co., Ltd. Nouvelle utilisation de composes tricycliques
FR2845385B1 (fr) * 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
FR2845384B1 (fr) * 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
AU2003279442A1 (en) * 2002-10-04 2004-04-23 Laboratoires Fournier S.A. 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR956150A (fr) * 1950-01-26
BE550650A (fr) * 1955-08-30
IL66242A0 (en) * 1981-07-23 1982-11-30 Erba Farmitalia N-imidazolyl derivatives of 1,2,3,4-tetrahydro-naphthalene,indan and 2-substituted-1-chroman,their preparation and pharmaceutical compositions containing them
JPH0629943B2 (ja) * 1983-10-31 1994-04-20 富士写真フイルム株式会社 画像形成方法
JPH01187543A (ja) * 1988-01-21 1989-07-26 Mitsubishi Paper Mills Ltd 写真用分光増感色素
FR2694290B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5554607A (en) * 1995-11-28 1996-09-10 American Home Products Corporation Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of atherosclerosis

Also Published As

Publication number Publication date
WO1997019932A1 (fr) 1997-06-05
EP0876355A1 (fr) 1998-11-11
AU1127697A (en) 1997-06-19
JP2000501100A (ja) 2000-02-02

Similar Documents

Publication Publication Date Title
JP5723357B2 (ja) 結晶質トリペプチドエポキシケトンプロテアーゼ阻害剤
JP2006505571A (ja) 置換されたインドール及びｈｃｖ阻害剤としてのその使用
CZ20021293A3 (cs) Léčivo k léčbě maligních nádorů
US5554607A (en) Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of atherosclerosis
JPH07509248A (ja) ラパマイシン誘導体
KR20050051658A (ko) ＩｇＥ를 조절하고 세포 증식을 억제하기 위한 페닐-인돌화합물
JPH07508035A (ja) ４−アザステロイド５α−レダクターゼ阻害剤
CA2238762A1 (fr) Derives 2-thioxo-imidazolin-4-one et leur utilisation pour augmenter la cholesterolemie a lipoproteine de haute densite
WO2007131034A1 (fr) Derives de pyrimidone actifs en tant que modulateurs de la proteine de choc thermique (hsp) 70
US5783707A (en) 2-thioxo-imidazolidin-4-one derivatives
WO1997019931A1 (fr) Derives de 2-(substitution sulfanyle)-3,5-dihydroimidazol-4-one
WO1996038445A1 (fr) Nouveaux derives de naphtyridine
CN114007602A (zh) 治疗果糖相关病症或疾病的新型化合物和使用方法
JPH05320049A (ja) アゾール誘導体を含有する抗アロマターゼ剤
WO2018113758A1 (fr) Amidine sulfonyle utilisée comme inhibiteur de l'indoleamine-2,3-dioxygénase, sa méthode de préparation et son utilisation
CA3039070A1 (fr) Inhibiteurs d'interactions mtor-deptor et leurs procedes d'utilisation
JP3718890B2 (ja) Ｎ−ベンゾイルプロリンエステル誘導体
JP4277015B2 (ja) ストレプトグラミン誘導体、その製造およびそれを含む製薬組成物
TW200409633A (en) Treatment of diabetes and diabetic complications with NHE-1 inhibitors
JP2002515912A (ja) 目に関連する病気の処置のためのソマトスタチン作動因子及び拮抗因子の利用
US5641762A (en) Bone targeted inhibitors of carbonic anhydrase
JPH03503407A (ja) ２４ｒ‐スキムノールならびにその製造および使用
CN101203498A (zh) 包括可代谢部分的杂环抗病毒化合物及其用途
US5861517A (en) 2-thioxo-imidazolidin-4-one derivatives
CN109293588A (zh) 一种具有ido1/tdo双靶点的小分子化合物及其制备方法与应用

Legal Events

Date Code Title Description
FZDE Dead